The roles of CD147 in the progression of gliomas.
Gliomas are characterized by their invasiveness, angiogenesis, glycolysis and poor prognosis. Determining how to inhibit angiogenesis and glycolysis and induce cell death in gliomas is essential to the development of an effective therapy. CD147, a highly glycosylated transmembrane glycoprotein with two Ig-like extracellular domains that belongs to the immunoglobulin superfamily, plays an important role in the regulation of tumor invasiveness, angiogenesis and glycolysis by inducing the secretion of matrix metalloproteinases and vascular endothelial growth factor and by interacting with monocarboxylate transporters. In this review, we first summarize the roles played by CD147 in gliomas and then propose that CD147 may be a complementary prognostic biomarker and a possible therapeutic target for glioma treatment.
['Fei|Fei|F|', 'Li|Sanzhong|S|', 'Fei|Zhou|Z|', 'Chen|Zhinan|Z|']
D000818:Animals D051926:Basigin D014408:Biomarkers, Tumor D018450:Disease Progression D005910:Glioma D006019:Glycolysis D006801:Humans D058990:Molecular Targeted Therapy D009361:Neoplasm Invasiveness D009389:Neovascularization, Pathologic D011379:Prognosis
CD147 glioma invasiveness angiogenesis glycolysis